Faget et al., 2023 - Google Patents
p38MAPKα stromal reprogramming sensitizes metastatic breast cancer to immunotherapyFaget et al., 2023
View HTML- Document ID
- 15283353053049622293
- Author
- Faget D
- Luo X
- Inkman M
- Ren Q
- Su X
- Ding K
- Waters M
- Raut G
- Pandey G
- Dodhiawala P
- Ramalho-Oliveira R
- Ye J
- Cole T
- Murali B
- Zheleznyak A
- Shokeen M
- Weiss K
- Monahan J
- DeSelm C
- Lee A
- Oesterreich S
- Weilbaecher K
- Zhang J
- DeNardo D
- Stewart S
- Publication year
- Publication venue
- Cancer discovery
External Links
Snippet
Metastatic breast cancer is an intractable disease that responds poorly to immunotherapy. We show that p38MAPKα inhibition (p38i) limits tumor growth by reprogramming the metastatic tumor microenvironment in a CD4+ T cell-, IFNγ-, and macrophage-dependent …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marin et al. | Cellular senescence is immunogenic and promotes antitumor immunity | |
| Chen et al. | Senescence rewires microenvironment sensing to facilitate antitumor immunity | |
| Corgnac et al. | CD103+ CD8+ TRM cells accumulate in tumors of anti-PD-1-responder lung cancer patients and are tumor-reactive lymphocytes enriched with Tc17 | |
| Cho et al. | Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion | |
| Quaranta et al. | Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer | |
| Georgoudaki et al. | Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis | |
| Warda et al. | CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor–engineered T cells | |
| Poropatich et al. | OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity | |
| Jackson et al. | Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma | |
| Peng et al. | Single-cell analysis reveals EP4 as a target for restoring T-cell infiltration and sensitizing prostate cancer to immunotherapy | |
| Huang et al. | Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion | |
| LaMarche et al. | An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis | |
| Akbay et al. | Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | |
| Urdinguio et al. | Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors | |
| Zhou et al. | Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras | |
| Van de Velde et al. | Neuroblastoma formation requires unconventional CD4 T cells and arginase-1–dependent myeloid cells | |
| Slevin et al. | Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis | |
| Faget et al. | p38MAPKα stromal reprogramming sensitizes metastatic breast cancer to immunotherapy | |
| Kim et al. | Hybrid Fc‐fused interleukin‐7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy | |
| Mempel et al. | Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response | |
| Chen et al. | Combining an alarmin HMGN1 peptide with PD-L1 blockade results in robust antitumor effects with a concomitant increase of stem-like/progenitor exhausted CD8+ T cells | |
| Zhang et al. | Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice | |
| Hundeyin et al. | Innate αβ T cells mediate antitumor immunity by orchestrating immunogenic macrophage programming | |
| Zeng et al. | Investigating T cell immunity in cancer: achievements and prospects | |
| Wang et al. | Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death |